Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tradipitant - Vanda Pharmaceuticals

Next Previous
Drug Profile

Tradipitant - Vanda Pharmaceuticals

Alternative Names: LY-686017; VLY 686

Latest Information Update: 14 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
  • Class Anti-inflammatories; Antipruritics; Antivirals; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Gastrokinetics; Pyridines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Motion sickness
  • Phase III Atopic dermatitis; COVID 2019 infections; Gastroparesis
  • Phase II Dyspepsia; Nausea and vomiting; Pruritus
  • Discontinued Alcoholism; Social phobia

Most Recent Events

  • 04 Dec 2025 The US FDA lifts partial clinical hold from VP-VLY-686-3403 protocol in Motion sickness (NCT06138613)
  • 28 Nov 2025 Preregistration for Nausea and vomiting (Prevention) in USA (PO)
  • 28 Nov 2025 The US Food and Drug Administration (FDA) accepts re-review of the partial clinical hold for tradipitant for Motion sickness

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top